Stocks
bioAffinity Technologies, Inc.BIAF
NASDAQHealthcareBiotechnology$2.80
Price as of · delayed, not real-time
A clinical-stage diagnostics company developing non-invasive tests for early cancer detection, with a focus on lung and bladder cancers. Its lead product, CyPath Lung, uses flow cytometry to detect malignant cells in sputum samples, targeting high-risk patients with pulmonary nodules. Investors track the company for its potential to address a significant unmet need in early cancer diagnosis.
52W Range: $2.80-$80.70
Congressional Interest in bioAffinity Technologies, Inc. (BIAF)
No congressional trades have been disclosed for bioAffinity Technologies, Inc. (BIAF) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading BIAF?
No congressional trades found for this stock.